Azora says AT177 remains on schedule for human testing to start in the first half of 2027, and it added experienced leaders. But 9,924,260 preferred shares converted into common shares, and 3,006,341 more remain convertible, so the updates point in different directions.
The planned trial and experienced new leaders support Azora's drug effort. The share conversions increase the common-share count, and more preferred shares can still convert. The supplied text gives no quarter financial figures, so the company update points in different directions.
Follow Azora Therapeutics, Inc. (AZR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AZR